The table below shows NovoCure Ltd's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$174.06M
$167.20M
$158.81M
$154.99M
$155.09M
$150.36M
Cost of revenue
$38.93M
$44.73M
$41.47M
$38.52M
$35.37M
$34.65M
Gross profit
$135.13M
$122.47M
$117.33M
$116.47M
$119.72M
$115.70M
R&D
$58.34M
$54.03M
$55.83M
$53.78M
$51.88M
$54.95M
NVCR annual revenue (10-K history)
NovoCure Ltd reported annual revenue of $655.35M for fiscal year 2025. That is up 8.3% from $605.22M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $82.89M (FY 2016) to $655.35M. Figures come from the company's audited annual reports as filed with the SEC.